Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
Feasibility Study for the Development of a PFC Harmonic Filter Missing Link for Creation of Simultaneous Multi-Point Fast Charging Stations for Electric Vehicles (MultiCharge)

Framework: Horizon 2020 — Societal Challenges
Programme: Smart, green and integrated transport
Action type: SME instrument
Countries involved: United Kingdom
Call: Small business innovation research for Transport (H2020-SMEINST-1-2014, 2014)
Start date: 2015-03-01
End date: 2015-08-31
Duration (months): 6.0
Total project cost (EUR): 71429.0
EU funding (EUR): 50000.0
Participants: 1
Project status: CLOSED

Feasibility Study for the Development of a PFC Harmonic Filter The Missing Link for Creation of Simultaneous Multi-Point Fast Charging Stations for Electric Vehicles Whilst some manufacturers offer “multi-vehicle” charge points, all models investigated were found to be cosmetic combinations of plural charging points capable of charging multiple vehicles operating the same charging methodology. No instances of true multi vehicle chargers (ie many types of vehicle/charging system on charge at the same time) were found. This is due to the complexities arising around electrical harmonic interactions between vehicles under charge and the various charging methodologies. Sufficient work to define these has not been carried out and no vehicle or charger unit impact data is available over the longer term. Potential service providers face a choice between cosmetic combinations or multiple different charging stations, a costly option, low in flexibility. The MultiCharge project will deliver a comprehensive picture of the harmonics between different vehicles and charging methodologies, before using software modelling to analyse the interactions and develop a Harmonic Filter to enable true multi-vehicle charging. MultiCharge replaces the active electronic module and multiple transformers present in most current EV chargers, with a single 3 phase 440 volt main passive unit comprising a zigzag auto transformer, harmonic filter, interphase transformer & rectifier block and distribution bus & control unit. The project will deliver social and economic growth via increased uptake of cleaner to run, cheaper to use Electric Vehicles. We will achieve this through delivery of an affordable re-charging system based upon market leader Carroll & Meynell's own technology, patented buck boost units and zigzag transformer to enable significant reductions in the cost of providing appropriate electricity supply to EV charging stations.

Keywords: electric vehicles,charging,transport
EuroMix (EuroMix)

Framework: Horizon 2020 — Societal Challenges
Programme: Food security, sustainable agriculture and forestry, marine and maritime and inland water research and the bioeconomy
Action type: Research and Innovation actions
Countries involved: Spain,Italy,Iceland,Germany,Cyprus,Belgium,Switzerland,Belgium,Sweden,Switzerland,Norway,Greece,Slovenia,France,France,France,Czechia,United States,Netherlands,Netherlands,Denmark,United Kingdom,Canada,Brazil,United Kingdom
Call: Assessing the health risks of combined human exposure to multiple food-related toxic substances (H2020-SFS-2014-2, 2014)
Start date: 2015-05-15
End date: 2019-05-14
Duration (months): 48.0
Total project cost (EUR): 8821295.56
EU funding (EUR): 7999097.0
Participants: 27
Project status: CLOSED

Euromix aim to develop an experimentally verified, tiered strategy for the risk assessment of mixtures of multiple chemicals derived from multiple sources across different life stages. The project takes account of the gender dimension and balances the risk of chemicals present in foods against the benefits of those foods. Important concepts for this new strategy are prioritisation criteria for chemicals based on their exposure and hazard characteristics and evaluation of the role of mode of action in grouping chemicals into cumulative assessment groups. In-silico and in-vitro tools will be developed and verified against in-vivo experiments, with focus on four selected endpoints (liver, hormones, development and immunology) to provide a full proof-of-principle. The EuroMix project will result in an innovative platform of bioassays for mixture testing and refined categorisation of chemicals in cumulative assessment groups. New hazard and exposure models will be embedded in a model toolbox, made available for stakeholders through an openly accessible web-based platform. Access to the web-based tools will be facilitated by training. Criteria will be set and guidance will be written on how to use and implement the tiered test strategy. Dissemination and harmonisation of the approach within EU, Codex Alimentarius, and WHO will be achieved by involving a.o. WHO and US-EPA in the project and by the participation of experts playing a key role in helping establish international food safety policies. It is expected that the new mechanism-based strategy, the bioassay platform, the openly accessible web-based model toolbox, and clear guidance on a tiered hazard and exposure test and risk assessment strategy will boost innovation in the public and private sector, provide a sound scientific basis for managing risks to public health from chemical mixtures, ultimately reduce the use of laboratory animals, and support the global discussion of risk assessment policies for mixtures.

Keywords: exposure assessment,in vitro testing,toxicogenomics
Phytotoxicolgical Risk of pharmaceuticals in soils (PhytoPharm)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Standard European Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Environment and Geosciences
Countries involved: United Kingdom
Call: Marie Skłodowska-Curie Individual Fellowships (IF-EF) (H2020-MSCA-IF-2015, 2015)
Start date: 2017-08-01
End date: 2019-07-31
Duration (months): 24.0
Total project cost (EUR): 183454.8
EU funding (EUR): 183454.8
Participants: 1
Project status: CLOSED

Pharmacueticals in the agricultural environment pose a risk to the continued productivity of the crop producing industry. To gain a better understanding of the processes involved in plant exposure and bioavailability of pharmaceutical compounds, a systematic approach is proposed to characterize the mobility of a study compound from soil to pore water in twenty native soils selected to represent a broad range of soil chemical-physical properties. Characterization of resulting pore water conditions will be used to study the interactions between pore water and plants. Analytical methods will be utilized to determine mobility of the compound in soil, pore water, and plant tissue. Monitoring of 18 plant development endpoints will reveal phyto-toxicological risk associated with pharmaceutical exposure. These interactions will be used to construct and validate a landscape scale spatial model. Data gathered throughout this study as well as the resulting model will provide the first attempt at landscape scale analysis for terrestrial environmental risk assessment from emerging contaminants. Identifying potential risks will help insure the stability and productivity of the agricultural economy into the future. Further, the adaptability of the model to different geographic regions, outside England and Wales, allows for the emergence of research collaboration across the world.

Keywords: emerging contaminants,phytotoxicology,antibiotics
Wildcat Economics: Informal Mining and Gold from the Global Margins in Contemporary Latin America (WILDCAT)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Standard European Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Social Sciences and Humanities
Countries involved: Denmark
Call: Individual Fellowships (H2020-MSCA-IF-2016, 2016)
Start date: 2017-06-01
End date: 2019-12-31
Duration (months): 24.0
Total project cost (EUR): 212194.8
EU funding (EUR): 212194.8
Participants: 1
Project status: CLOSED

The proposed project will conduct an ethnographic study of small-scale gold mining in South America, otherwise known as ‘wildcat mining’, and aims to explore the interconnection between formal and informal economic spheres at the global margins. The project will forge a concept of ‘wildcat economics’: that is, the particular form of small-scale mining that takes place in extremely remote regions of the world essentially ‘under the radar’, in this case the Amazonian rainforest. As such, WILDCAT will explore forms of globalization that do not comprise direct corporate growth, but emerge from individual ventures, and thus challenges stereotypical renditions of resource extraction and global capitalism. Through this analytical framework, the project provides insights into lesser-understood workings of globalization by offering new ways of conceptualizing the jurisdictions of global capitalism and the economic activities that lie beyond its limits. Fieldwork will take place in the Madre de Dios region of Peru where wildcat mining activity is clustered, and will draw on methodologies of both anthropology and geography. I will significantly benefit from a placement at the University of Copenhagen as it is one of the key European centers for the study of Resource Extraction and Management. Significantly, Copenhagen University houses the Centre for Sustainable Artisanal and Small-Scale Mining (SASMin), which explores the activities and issues associated with small-scale mining around the world. I will be affiliated with this centre as a researcher representing and bringing insights from the discipline of anthropology.

Keywords: resource extraction,small scale mining,latin america,remoteness,anthropology,amazonia
Diagnostic drug response-profiling using SLAMseq (SLAM-Dx)

Framework: Horizon 2020 — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Proof of concept grants
Action type: ERC actions
Panel: Physiology in Health, Disease and Ageing
Panel description: Organ and tissue physiology, comparative physiology, physiology of ageing, pathophysiology, interorgan and tissue communication, endocrinology, nutrition, metabolism, interaction with the microbiome, non-communicable diseases including cancer (and except disorders of the nervous system and immunity-related diseases)
Countries involved: Austria
Call: ERC Proof of Concept Grant (ERC-2019-PoC, 2019)
Start date: 2019-10-01
End date: 2021-03-31
Duration (months): 18.0
Total project cost (EUR): 150000.0
EU funding (EUR): 150000.0
Participants: 1
Project status: CLOSED

One of the greatest challenges today is to select the right drug for the right patient at the right time. A lack of diagnostic tools for predicting therapy response currently hampers patient-tailored treatment decisions in the clinic with severe implications for economy and – most importantly – patient survival. Profiling transcriptional responses to drug treatment is a key method for probing the activity of targeted therapeutics and guiding their use in the clinic. A major limitation of established gene expression profiling techniques (such as microarrays and RNA-seq) is their limited time resolution precluding the distinction of direct from secondary transcriptional responses to drug therapy. This hampers their utility for deciphering drug action and guiding patient-tailored treatment decisions. To overcome this problem, as part of an ERC-StG project (Systematic in-vivo analysis of chromatin-associated targets in leukemia, 336860) I have co-developed thiol(SH)-linked alkylation for the metabolic sequencing of RNA (SLAMseq) as a rapid, robust and highly scalable method for the unbiased quantification of changes in mRNA production upon cell perturbations. Its unique features (low input cell numbers, short treatment-to-sample time, 1-day protocol library preparation in 96-well format) may qualify SLAMseq as the first method to probe the function, efficacy and selectivity of candidate therapeutics in primary (tumor) cells with unprecedented precision and on a large scale. In this ERC-PoC project, I propose to establish technical and commercial proof-of-concept for SLAMseq’s application in preclinical and clinical drug development and optimization, and for patient-tailored treatment selection. Upon the successful proof-of-concept for SLAMseq’s application as diagnostic tool, SLAM-Dx has the potential to revolutionize translational research and personalised medicine in a variety of disease areas.

Keywords: slamseq,drug response,diagnostic,personalised medicine,drug development
Regulation of mammalian genes by new classes of promoter proximal transcription start sites (uTSSreg)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Standard European Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Life Sciences
Countries involved: Denmark
Call: Individual Fellowships (H2020-MSCA-IF-2018, 2018)
Start date: 2020-04-01
End date: 2022-03-31
Duration (months): 24.0
Total project cost (EUR): 219312.0
EU funding (EUR): 219312.0
Participants: 1
Project status: CLOSED

Regulation and fidelity of gene expression is fundamental to the differentiation and maintenance of living organisms. Moreover, understanding how genes are regulated is an essential research question of importance for biomedical application. Although our knowledge about key factors influencing gene expression has increased substantially over the past years, the complexity of gene expression regulation remains elusive. In this project, I intend to discover novel gene expression regulatory circuits operating in mammalian genomes facilitated by pervasive transcription. Although some scattered examples of how pervasive transcription may regulate gene promoter activity exist, no systematic study has been conducted. Here, I will address this question by using a new protein depletion strategy, developed in the host laboratory, to inactivate the nuclear exosome, a major 3’-to-5’ ribonuclease complex, and its co-factors in HeLa and mouse embryonic stem (mES) cells, thus, to create an ideal situation to observe ‘hidden’ cellular transcription events, which would not normally be visible. I intend to assess whether and how this ‘hidden’ transcription contributes to the regulation of promoter activity in HeLa and mES cells, further expanding our knowledge of the regulation of protein-coding genes and ultimately revealing the extent of regulation instigated by pervasive transcription. This study will lay a foundation for future research in the field and at the same time provide novel conceptual information, which might be exploited in prevention or treatment of human diseases.

Keywords: rna degradation,exosome,unstable tss
Optimization of Medical Accelerators (OMA)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Innovative Training Networks (ITN)-European Training Networks
Action type: Marie Skłodowska-Curie actions
Panel: Life Sciences
Countries involved: Germany,Spain,Germany,Spain,Italy,Italy,Austria,Germany,Belgium,Switzerland,Switzerland,Slovenia,Netherlands,United Kingdom,United Kingdom,United Kingdom,United Kingdom
Call: Marie Skłodowska-Curie Innovative Training Networks (ITN-ETN) (H2020-MSCA-ITN-2015, 2015)
Start date: 2016-02-01
End date: 2020-01-31
Duration (months): 48.0
Total project cost (EUR): 3852879.13
EU funding (EUR): 3852879.13
Participants: 24
Project status: CLOSED

Cancer is a major social problem, and it is the main cause of death between the ages 45-65 years. In the treatment of cancer, radio therapy (RT) plays an essential role. RT with hadrons (protons and light ions), due to their unique physical and radiobiological properties, offers several advantages over photons for specific cancer types. In particular, they penetrate the patient with minimal diffusion, they deposit maximum energy at the end of their range, and they can be shaped as narrow focused and scanned pencil beams of variable penetration depth. Although significant progress has been made in the use of particle beams for cancer treatment, an extensive research and development program is still needed to maximize the healthcare benefits from these therapies. The Optimization of Medical Accelerators (OMA) is the aim of the here-proposed European Training Network, in line with the requirements of the EC’s Medical Exposure Directive. OMA joins universities, research centers and clinical facilities with industry partners to address the challenges in treatment facility design and optimization, numerical simulations for the development of advanced treatment schemes, and in beam imaging and treatment monitoring. The proposed R&D program ranges from life sciences (oncology, cell and micro biology and medical imaging.), physics and accelerator sciences, mathematics and IT, to engineering. It is hence ideally suited for an innovative training of early stage researchers. By closely linking all above research areas, OMA will provide an interdisciplinary education to its Fellows. This will equip them with solid knowledge also in research areas adjacent to their core research field, as well as with business competences and hence give them a perfect basis for a career in research.

Keywords: particle beam therapy,bragg peak,imaging techniques,beam diagnostics,cell biology,oncology,monte carlo simulations,treatment planning,ion beam therapy,heavy ions
Graphene curvature, flexibility and reactivity control by means of external fields: theory and computer simulations (GRAFLEX)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Career Restart panel
Action type: Marie Skłodowska-Curie actions
Panel: Physics
Countries involved: Italy
Call: Marie Skłodowska-Curie Individual Fellowships (IF-EF) (H2020-MSCA-IF-2014, 2014)
Start date: 2015-09-08
End date: 2017-09-07
Duration (months): 24.0
Total project cost (EUR): 180277.2
EU funding (EUR): 180277.2
Participants: 1
Project status: CLOSED

Graphene is a unique material with high potential for applications from high-tech to bio-tech. These capabilities are directly connected to graphene flexibility and electronic properties, as well as to the possibility of controlling them by chemical functionalization. Curvature related reactivity enhancement was shown, and curvature control has found several possible applications from H-storage and energy harvesting to biomed engineering. Thus, the control of graphene curvature is of high relevance. The aim of GRAFLEX is to investigate the process of curvature control by means of external electric- and electromagnetic fields (EMF), and the consequent curvature-dependent interaction with H, specifically focusing on the physis- to chemi-sorption reversible conversion. EMF in the range of THz will be chosen, since coherent graphene vibrations at those frequencies correspond to the traveling nano-sized ripples producing a local dynamical modulation of the curvature. To achieve this, we propose to use a state-of-the-art density functional (DF), DF perturbation, and trajectory based time dependent DF theories in combination with ab initio investigation of the kinetics and calculation of flexoelectricity response to the strain gradient in curved graphene. Conducting the proposed research after carrier break will help the proponent to resume research activities and to train in 1)using the most advanced theoretical methods to investigate properties in graphene/hydrogen system; 2)observe time-resolved information to exploit curvature control process. The complementarity expertise of researchers at NANO@NEST group of multi-scale simulations and proponent’s extensive experience trajectory based chemical dynamics, kinetics and quantum chemistry, together with attractive working conditions, guarantee the feasibility of this challenging project.The experience gained by the proponent within GRAFLEX will change her carrier path to attain an independent position in academia in Europe

Keywords: curved and rippled graphene,flexoelectricity,hydrogen graphene interaction,density functional theory,ab initio molecular dynamics computer simulations
Strengthening management at district level to support the achievement of Universal Health Coverage (PERFORM2scale) (Perform 2 scale)

Framework: Horizon 2020 — Societal Challenges
Programme: Health, demographic change and wellbeing
Theme: Health care provision and integrated care
Action type: Research and Innovation actions
Countries involved: Ireland,Ireland,Uganda,Switzerland,Netherlands,Ghana,United Kingdom,Malawi,United Kingdom
Call: Implementation research for scaling-up of evidence based innovations and good practice in Europe and low- and middle-income countries (H2020-SC1-2016-RTD, 2016)
Start date: 2017-01-01
End date: 2022-03-31
Duration (months): 63.0
Total project cost (EUR): 7689008.66
EU funding (EUR): 6749280.33
Participants: 9
Project status: SIGNED

The new challenge in global health is to achieve Universal Health Care (UHC) by 2030. Having an adequate workforce is critical to achieving UHC. Efforts are in place to scale up the numbers of health workers. Improving health workforce performance is equally important as the quantity of health workers, but more challenging. Workforce performance improvement can be achieved better at management levels close to front-line workers. The PERFORM project developed a problem-based management strengthening intervention for management teams at district level in three African countries to improve both health workforce performance and service delivery more generally. The evaluation of the management strengthening intervention (MSI) demonstrated its effectiveness in enabling the management teams to solve workforce performance and other problems locally which improved service delivery, and become better managers. To have a wider impact and thus contribute to the achievement of UHC the PERFORM management strengthening intervention needs to be scaled up and embedded. The aim of PERFORM2scale is to develop and evaluate a sustainable approach to scaling up a district level management strengthening intervention in different and changing contexts. A framework and strategy for scaling up the intervention will be developed with government agencies in Ghana, Malawi and Uganda each country. Capacity will be developed to implement the scale-up which will be carried out over three years in order to use the MSI at scale and embed the process at district level. The scale-up framework and strategy will be subjected to process evaluation (to identify opportunities and barriers) and outcome evaluation. Both the framework and strategy will be validated for use in the study countries and elsewhere for use and adaptation. The use of the management strengthening intervention at scale in countries will be a major contribution to achieving UHC.

Keywords: management development,action research,human resources for health,district management,africa